Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 25, No 12 (April 20), 2007: pp. 1606-1620
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.0442

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fecher, L. A.
Right arrow Articles by Alani, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fecher, L. A.
Right arrow Articles by Alani, R. M.

BIOLOGY OF NEOPLASIA

Toward a Molecular Classification of Melanoma

Leslie A. Fecher, Staci D. Cummings, Megan J. Keefe, Rhoda M. Alani

From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and the Departments of Oncology and Pharmacology and Molecular Sciences, Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Address reprint requests to Rhoda M. Alani, MD, Johns Hopkins University School of Medicine, 1650 Orleans St, CRB 342, Baltimore, MD 21231-1000; e-mail: ralani{at}jhmi.edu

The incidence of melanoma is increasing at one of the highest rates of any form of cancer in the United States, with the current lifetime risk being one in 68. At present, there are limited systemic therapies to treat advanced stages of melanoma, and the key to improved survival remains early detection. Recent discoveries have allowed for a clearer picture of the molecular events leading to melanoma development and progression. Since identifying prevalent activating mutations of the BRAF kinase in melanomas, there has been a flood of additional molecular studies to further clarify the role of this pathway and others in melanomagenesis. In particular, recent genetic studies have demonstrated specific genotype-phenotype correlations that provide the first major insights into the molecular subclassification of melanoma and the heterogeneous nature of this malignancy. In this article, we review the most up-to-date molecular discoveries in melanoma biology and provide a framework for understanding their significance in melanoma development and progression. We also provide details on the development of novel therapies based on these recent molecular discoveries and insight into current and planned clinical trials. It is expected that these latest studies in melanoma will help define the critical molecular events involved in disease onset and progression and allow us to move rapidly toward a true molecular classification. We eagerly anticipate rationally designed melanoma therapies based on such a classification scheme and the associated improvements in patient outcomes.

Supported by Grant No. CA107017 from the National Cancer Institute, the Flight Attendant Medical Research Institute, and the Joanna M. Nicolay Melanoma Foundation.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
D. L. Sheridan, Y. Kong, S. A. Parker, K. N. Dalby, and B. E. Turk
Substrate Discrimination among Mitogen-activated Protein Kinases through Distinct Docking Sequence Motifs
J. Biol. Chem., July 11, 2008; 283(28): 19511 - 19520.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. S. Hodi, P. Friedlander, C. L. Corless, M. C. Heinrich, S. Mac Rae, A. Kruse, J. Jagannathan, A. D. Van den Abbeele, E. F. Velazquez, G. D. Demetri, et al.
Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
J. Clin. Oncol., April 20, 2008; 26(12): 2046 - 2051.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
F. L. Meyskens Jr. and M. Berwick
UV or Not UV: Metals Are The Answer
Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 268 - 270.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online